# Idarucizumab for Dabigatran Reversal

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/idarucizumab-for-dabigatran-reversal/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Charles V. Pollack,Paul A. Reilly,John W. Eikelboom,Stephan Glund,Peter Verhamme,Richard A. Bernstein,Robert Dubiel,Menno V. Huisman,Elaine M. Hylek,Pieter W. Kamphuisen,Jörg Kreuzer,Jerrold H. Levy,Frank W. Sellke,Joachim Stangier,Thorsten Steiner,Bushi Wang,CW Kam,Jeffrey I. Weitz |
| Citations | 1,460 |
| DOI | 10.1056/nejmoa1502000 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1513839038 |
| PMID | 26095746 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Jerrold H. Levy](https://scholariq.org/researchers/jerrold-h-levy/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Paper topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.